



Investment Case

March 2023

WisdomTree BioRevolution UCITS ETF



WisdomTree.eu
+44 (0) 207 448 4330

WisdomTree BioRevolution UCITS ETF

If the 19th century was the century of chemistry and the 20th century was the century of physics, we believe the 21st century will be defined by developments in biology.

Revolutionary advances across multiple fields including computer science, artificial intelligence, big data analytics, automation, chemistry, biology and engineering are creating previously unimaginable new opportunities to re-engineer biological systems in ways that will revolutionise healthcare, agriculture, manufacturing, energy production, consumer services and data storage.

In our view, the 'Biorevolution Megatrend' will have the capacity to transform how we do things like improve longevity, fight disease, provide food and more.

Partnership for BioRevolution Expertise: Dr Jamie Metzl

WisdomTree continues its expert-partner driven model for thematic investing, this time with **Dr Jamie Metzl**, a leading technology futurist. Dr. Metzl is known for writing the book *Hacking Darwin: Genetic Engineering and the Future of Humanity*. He also serves as a member of the World Health Organization's expert committee on human genome editing.

WisdomTree and Dr Metzl share the view that the application of genetics and biotechnology will extend far beyond healthcare. We may look back and view it in a similar light as we have seen the industrial and internet revolutions.

The WisdomTree BioRevolution ESG Screened Index leverages the data and expertise from Dr Metzl, and identifies the **key sectors and industry verticals** that are expected to be most significantly transformed by advances in biological science and technology, as well as the companies to be most representative of this wave of innovation.

Key BioRevolution Sectors

Human Health	Agriculture & Food	Materials, Chemicals, & Energy	Biological Machines & Interfaces
<p>The application of genetic technologies to prevent and treat disease will lead to significant enhancements to human health, well being, and longevity.</p> <ul style="list-style-type: none"> • Diagnostics & Surveillance • Precision Health/ Gene • Therapies • Regenerative • Medicine/Stem Cell • Vaccines 	<p>The genetics and biotechnology revolutions will increasingly transform agriculture, aquaculture, and food production, creating healthier and more sustainable models for feeding our growing population.</p> <ul style="list-style-type: none"> • Precision Agriculture • Plant Based Meats • Cellular Agriculture 	<p>Biological reengineering will be used to produce on increasing percentage of the physical inputs needed for manufacturing.</p> <ul style="list-style-type: none"> • Synthetic Manufacturing and Precision Fermentation • Biofuels 	<p>DNA has approximately one million times greater storage capacity than hard disk storage.</p> <ul style="list-style-type: none"> • DNA Data Storage • Bioloical Computers • Brain Machine Interfaces

Source: WisdomTree, Jamie Metzl.

The WisdomTree BioRevolution ESG Screened Index

The **time horizon and success of commercial adoption** of each BioRevolution application will vary, which is why at WisdomTree we believe the diverse portfolio of companies with **sector diversification** and **reduced concentration risk** is the best way for investors to gain exposure to the **BioRevolution megatrend**.

Selection of companies

The Index is designed to take a broad focus within the key BioRevolution sectors with significant potential to be transformed by advancements in genetics and biotechnology. At WisdomTree we define such advancements as **BioRevolution activities** with some examples presented below:

Application of genetic technologies to prevent and treat disease

Application of human genetic technologies to new classes of consumer products personalised for each individual

Transformation of agriculture, aquaculture and food production

More sustainable models for feeding the growing global population

Biological re-engineering used to produce an increasing percentage of the physical inputs needed for manufacturing

DNA as a storage solution

As is the case for any index, there are criteria that define **general eligibility requirements**. Some of these include:

Incorporation, domicile and equity listing within eligible developed market countries

Minimum market capitalisation of \$300 million

Average daily dollar volume greater than \$1,000,000 for each of the three months preceding screening

Companies that are representative of the aforementioned BioRevolution activities and sectors are selected for inclusion in the Index.

These companies are then subjected to the ESG screening criteria defined within the WisdomTree ESG framework. For information on the WisdomTree approach to Environmental, Social and Governance (ESG), visit our [responsible investing page](#).

Weighting

The Index is a **modified equally weighted** Index and will reconstitute on a **semi-annual basis** in October and April.

The full methodology document that includes all relevant index details would be available on WisdomTree's [website](#).

Fund information: WisdomTree BioRevolution UCITS ETF

Ticker	Exchange	ISIN	BBG Code	Reuters Code	Listing Currency	Base Currency	TER%
WDNA	LSE	IE000O8KMPM1	WDNA LN	WDNA.L	USD	USD	0.45%
WBIO	LSE	IE000O8KMPM1	WBIO LN	WTWBIO.L	GBx	USD	0.45%
WDNA	Borsa Italiana	IE000O8KMPM1	WDNA IM	WDNA.MI	EUR	USD	0.45%
WRNA	XETRA	IE000O8KMPM1	WRNA GY	WRNA.DE	EUR	USD	0.45%
WDNA	SIX	IE000O8KMPM1	WDNA SY	WDNA.S	USD	USD	0.45%

TER: Total Expense Ratio.

Important Information

Marketing communications issued in the European Economic Area (“EEA”): This document has been issued and approved by WisdomTree Ireland Limited, which is authorised and regulated by the Central Bank of Ireland.

Marketing communications issued in jurisdictions outside of the EEA: This document has been issued and approved by WisdomTree UK Limited, which is authorised and regulated by the United Kingdom Financial Conduct Authority.

WisdomTree Ireland Limited and WisdomTree UK Limited are each referred to as “WisdomTree” (as applicable). Our Conflicts of Interest Policy and Inventory are available on request.

For professional clients only. Past performance is not a reliable indicator of future performance. Any historical performance included in this document may be based on back testing. Back testing is the process of evaluating an investment strategy by applying it to historical data to simulate what the performance of such strategy would have been. Back tested performance is purely hypothetical and is provided in this document solely for informational purposes. Back tested data does not represent actual performance and should not be interpreted as an indication of actual or future performance. The value of any investment may be affected by exchange rate movements. Any decision to invest should be based on the information contained in the appropriate prospectus and after seeking independent investment, tax and legal advice. These products may not be available in your market or suitable for you. The content of this document does not constitute investment advice nor an offer for sale nor a solicitation of an offer to buy any product or make any investment.

An investment in exchange-traded products (“ETPs”) is dependent on the performance of the underlying index, less costs, but it is not expected to match that performance precisely. ETPs involve numerous risks including among others, general market risks relating to the relevant underlying index, credit risks on the provider of index swaps utilised in the ETP, exchange rate risks, interest rate risks, inflationary risks, liquidity risks and legal and regulatory risks.

The information contained in this document is not, and under no circumstances is to be construed as, an advertisement or any other step in furtherance of a public offering of shares in the United States or any province or territory thereof, where none of the issuers or their products are authorised or registered for distribution and where no prospectus of any of the issuers has been filed with any securities commission or regulatory authority. No document or information in this document should be taken, transmitted or distributed (directly or indirectly) into the United States. None of the issuers, nor any securities issued by them, have been or will be registered under the United States Securities Act of 1933 or the Investment Company Act of 1940 or qualified under any applicable state securities statutes.

This document may contain independent market commentary prepared by WisdomTree based on publicly available information. Although WisdomTree endeavours to ensure the accuracy of the content in this document, WisdomTree does not warrant or guarantee its accuracy or correctness. Any third party data providers used to source the information in this document make no warranties or representation of any kind relating to such data. Where WisdomTree has expressed its own opinions related to product or market activity, these views may change. Neither WisdomTree, nor any affiliate, nor any of their respective officers, directors, partners, or employees accepts any liability whatsoever for any direct or consequential loss arising from any use of this document or its contents.

This document may contain forward looking statements including statements regarding our belief or current expectations with regards to the performance of certain assets classes and/or sectors. Forward looking statements are subject to certain risks, uncertainties and assumptions. There can be no assurance that such statements will be accurate and actual results could differ materially from those anticipated in such statements. WisdomTree strongly recommends that you do not place undue reliance on these forward-looking statements.

WisdomTree Issuer ICAV

The products discussed in this document are issued by WisdomTree Issuer ICAV (“WT Issuer”). WT Issuer is an umbrella investment company with variable capital having segregated liability between its funds organised under the laws of Ireland as an Irish Collective Asset-management Vehicle and authorised by the Central Bank of Ireland (“CBI”). WT Issuer is organised as an Undertaking for Collective Investment in Transferable Securities (“UCITS”) under the laws of Ireland and shall issue a separate class of shares (“Shares”) representing each fund. Investors should read the prospectus of WT Issuer (“WT Prospectus”) before investing and should refer to the section of the WT Prospectus entitled ‘Risk Factors’ for further details of risks associated with an investment in the Shares.

Notice to Investors in Switzerland – Qualified Investors

This document constitutes an advertisement of the financial product(s) mentioned herein.

The prospectus and the key investor information documents (KIID) are available from WisdomTree’s website: <https://www.wisdomtree.eu/en-ch/resource-library/prospectus-and-regulatory-reports>

Some of the sub-funds referred to in this document may not have not been registered with the Swiss Financial Market Supervisory Authority (“FINMA”). In Switzerland, such sub-funds that have not been registered with FINMA shall be distributed exclusively to qualified investors, as defined in the Swiss Federal Act on Collective Investment Schemes or its implementing ordinance (each, as amended from time to time). The representative and paying agent of the sub-funds in Switzerland is Société Générale Paris, Zurich Branch, Talacker 50, PO Box 5070, 8021 Zurich, Switzerland. The prospectus, the key investor information documents (KIID), the articles of association and the annual and semi-annual reports of the sub-funds are available free of charge from the representative and paying agent. As regards distribution in Switzerland, the place of jurisdiction and performance is at the registered seat of the representative and paying agent.

For Investors in France: The information in this document is intended exclusively for professional investors (as defined under the MiFID) investing for their own account and this material may not in any way be distributed to the public. The distribution of the Prospectus and the offering, sale and delivery of Shares in other jurisdictions may be restricted by law. WT Issuer is a UCITS governed by Irish legislation, and approved by the Financial Regulatory as UCITS compliant with European regulations although may not have to comply with the same rules as those applicable to a similar product approved in France. The Fund has been registered for marketing in France by the Financial Markets Authority (Autorité des Marchés Financiers) and may be distributed to investors in France. Copies of all documents (i.e. the Prospectus, the Key Investor Information Document, any supplements or addenda thereto, the latest annual reports and the memorandum of incorporation and articles of association) are available in France, free of charge at the French centralizing agent, Societe Generale at 29, Boulevard Haussmann, 75009, Paris, France. Any subscription for Shares of the Fund will be made on the basis of the terms of the prospectus and any supplements or addenda thereto.

For Investors in Malta: This document does not constitute or form part of any offer or invitation to the public to subscribe for or purchase shares in the Fund and shall not be construed as such and no person other than the person to whom this document has been addressed or delivered shall be eligible to subscribe for or purchase shares in the Fund. Shares in the Fund will not in any event be marketed to the public in Malta without the prior authorisation of the Maltese Financial Services Authority.

For Investors in Monaco: This communication is only intended for duly registered banks and/or licensed portfolio management companies in Monaco. This communication must not be sent to the public in Monaco.

For Investors in Israel: Offering materials for the offering of the Shares and securities have not been filed with or approved or disapproved by the United States Securities and Exchange Commission or any other state or federal regulatory authority, nor has any such regulatory authority passed upon or endorsed the merits of this offering or passed upon the accuracy or completeness of any offering materials. Any representation to the contrary is unlawful. The products mentioned herein have not been approved by the Israel Securities Authority and will only be distributed to Israeli residents in a manner that will not constitute “an offer to the public” under sections 15 and 15a of the Israel Securities Law, 5728-1968 (“the Securities Law”) or section 25 of the Joint Investment Trusts Law, 5754-1994 (“the Joint Investment Trusts Law”), as applicable. The products are being offered to a limited number of investors (35 investors or fewer during any given 12 month period) and/or those categories of investors listed in the First Addendum (“the Addendum”) to the Securities Law, “Sophisticated Investors”) who in each case have provided written confirmation that they qualify as Sophisticated Investors, and that they are aware of the consequences of such designation and agree thereto; in all cases under circumstances that will fall within the private placement or other exemptions of the Joint Investment Trusts Law, the Securities Law and any applicable guidelines, pronouncements or rulings issued from time to time by the Israel Securities Authority.

This prospectus or this document may not be reproduced or used for any other purpose, nor be furnished to any other person other than those to whom copies have been sent. Any offeree who purchases a product is purchasing such product for its own benefit and account and not with the aim or intention of distributing or offering such product to other parties (other than, in the case of an offeree which is a Sophisticated Investor by virtue of it being a banking corporation, portfolio manager or member of the Tel-Aviv Stock Exchange, as defined in the Addendum, where such offeree is purchasing a product for another party which is a Sophisticated Investor).

Nothing in this document should be considered investment advice or investment marketing as defined in the Regulation of Investment Counselling, Investment Marketing and Portfolio Management Law, 5755-1995. Investors are encouraged to seek competent investment counselling from a locally licensed investment counsel prior to making the investment. A recipient of this document may be required to provide confirmation that it is a Sophisticated Investor purchasing a product for its own account or, where applicable, for other Sophisticated Investors.



WisdomTree.eu
+44 (0) 207 448 4330